Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Diabetes Extends Feelers Into Other Diseases

Executive Summary

Eli Lilly leads the way in diabetes and is using its current portfolio to find advantageous opportunities in related therapeutic areas.

You may also be interested in...



Cigna’s Bradbury Talks PCSK9 Contracts And Value Versus Volume

Amgen and Sanofi/Regeneron will pay deeper discounts if patients taking Repatha and Praluent don’t experience similar levels of LDL-cholesterol lowering as was seen in clinical trials.

BI, Lilly To Study Jardiance As Heart Failure Therapy

Boehringer Ingelheim and Eli Lilly will launch two outcomes trials within the next 12 months investigating their jointly developed diabetes medicine Jardiance (empagliflozin) as a treatment for people with chronic heart failure – enrolling patients both with and without type 2 diabetes.

Jardiance To Change The Game In Diabetes

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

GB150366

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel